A number of other analysts have also recently weighed in on MDVN. Analysts at Summer Street raised their price target on shares of Medivation from $74.00 to $112.00 in a research note to investors on Wednesday, May 16th. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Medivation in a research note to investors on Monday, May 14th. They now have a $87.00 price target on the stock. Finally, analysts at Citigroup (NYSE: C) raised their price target on shares of Medivation from $90.00 to $129.00 in a research note to investors on Monday, May 14th.
Medivation opened at 81.64 on Monday. Medivation has a 1-year low of $14.32 and a 1-year high of $89.46. The company’s market cap is $2.959 billion.
Medivation last issued its quarterly earnings data on Tuesday, May 8th. The company reported $0.01 earnings per share for the quarter, missing the analysts’ consensus estimate of $1.19 by $1.18. Medivation’s revenue was up 150.3% compared to the same quarter last year. On average, analysts predict that Medivation will post $-0.70 earnings per share next quarter.
Medivation, Inc. is a biopharmaceutical company focused on the rapid development of small molecule drugs to treat serious diseases for which there are limited treatment options.